If you missed this announcement, you’re not alone. It wasn’t exactly front-page news.
On February 28, the FDA quietly revised the Box Warning on FDA-regulated testosterone therapy products. While they did not remove the warning entirely, they made a significant change.
First, What Is a Box Warning?
Box Warnings (formerly called Black Box Warnings) are the FDA’s most serious drug safety labels. They’re used to flag major risks associated with medications and currently apply to over 400 drugs – including testosterone.
For years, testosterone products have carried a Box Warning suggesting increased cardiovascular risk. But after mounting clinical evidence, especially from the TRAVERSE trial, the FDA has adjusted its position.
The Big Update: Cardiovascular Risk Removed
The TRAVERSE trial was a massive, high-quality randomized controlled trial. It confirmed what many of us already knew: testosterone therapy does not increase the risk of major adverse cardiovascular events (MACE) in men.
In response, the FDA removed language in the Box Warning that previously linked TRT to increased cardiovascular risk.
But They Didn’t Stop There
Instead of removing the warning completely, the FDA added two new cautionary notes:
- Blood Pressure Increases
- Clarification of Use
Blood Pressure Warnings
The FDA cited a few post-marketing studies from 2017 showing minor elevations in blood pressure among some TRT users. But this risk is likely overstated, especially when testosterone is dosed appropriately.
Blood pressure changes can occur with poor TRT protocols – usually from improper dosing schedules that spike aldosterone or estrogen levels. When therapy is optimized, the cardiovascular profile is typically neutral or even beneficial.
Still, it is a good idea to encourage home BP monitoring in patients with a history of hypertension.
Clarification of Use: The Real Agenda?
Here’s the exact quote from the FDA:
Testosterone is FDA-approved as replacement therapy only for men who have low testosterone levels due to disorders of the testicles, pituitary gland, or brain that cause a condition called hypogonadism. However, FDA has become aware that testosterone is being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging. The benefits and safety of this use have not been established.
This is the FDA drawing a line in the sand. They are signaling disapproval of TRT for age-related testosterone decline.
But here’s the issue: this stance ignores real clinical outcomes and the fact that many men benefit tremendously from properly dosed TRT, regardless of the cause.
What This Means for You as a Provider
- We won this round: The TRAVERSE trial gave us evidence-based validation of TRT’s cardiovascular safety.
- Update your consent forms to reflect the latest guidance:
- No increased MACE risk
- Possible BP changes
- FDA stance on aging-related hypogonadism
- Continue providing high-quality care that considers both labs and symptoms
TRT remains one of the most powerful tools in your HRT toolkit. And when used correctly, it is safe, effective, and transformative.
Want to Learn More?
Inside the HRTU Master Course, we break down:
- The TRAVERSE trial findings
- Proper TRT dosing protocols
- How to talk to patients about FDA warnings
- What to include in your informed consent documents
You will walk away with the tools to prescribe confidently and ethically—and that is exactly what your patients deserve.
